You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models

Alerts

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address